NCT00192855已完成不适用
Entacapone Augmentation for Schizophrenia- A Randomized Controlled Trial
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- Improvement in specific rating scales during the study and after completion, compared to baseline.
研究概览
简要总结
This study is testing the hypothesis that Entacapone added to ongoing antipsychotic treatment can be beneficial in schizophrenic patients with negative symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •predominantly negative symptoms
- •stable on ongoing antipsychotic treatment
排除标准
- •acute psychotic exacerbation
- •suicidal ideation
- •uncontrolled systemic disease
结局指标
主要结局
Improvement in specific rating scales during the study and after completion, compared to baseline.
时间窗: Baseline and once a month untill end of study
次要结局
- Change in PANSS score.(Before and after intervention)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Amantadine as Adjunctive Therapy to Antipsychotics in SchizophreniaSchizophreniaNCT00999505Hospital de Clinicas de Porto Alegre40
已完成
4 期
A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational ProgrammeWeight GainNCT00191828Eli Lilly and Company60
已完成
4 期
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With SchizophreniaSchizoaffective DisorderSchizophreniform DisordersSchizophreniaNCT00595504Massachusetts General Hospital25
招募中
4 期
"Extended" (Alternate Day) Antipsychotic DosingSchizophrenia and Related DisordersAntipsychotic AgentsDrug Administration ScheduleDrug TherapyNCT04478838Centre for Addiction and Mental Health120
终止
3 期
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic SyndromeBipolar I DisorderMetabolic SyndromeSchizophreniaSchizoaffective DisorderNCT00857818Otsuka Pharmaceutical Development & Commercialization, Inc.64